CAS: 2290608-13-6
| Marke | Produktdaten | Reinheit | Preisklasse | Voraussichtliche Lieferung |
|---|---|---|---|---|
 | N-Methyl-3-(1-methyl-1H-imidazol-4-yl)-4-((4-(trifluoromethyl)phenyl)amino)benzenesulfonamide REF: 3D-QRD60813CAS: 2290608-13-6 | Min. 95% | Nachfragen | Di 21 Jan 25 |
 | VT103 REF: TM-T62077CAS: 2290608-13-6 | 98.73% | 121,00 €~3.690,00 € | Di 28 Jan 25 |
N-Methyl-3-(1-methyl-1H-imidazol-4-yl)-4-((4-(trifluoromethyl)phenyl)amino)benzenesulfonamide
CAS:2290608-13-6
Please enquire for more information about N-Methyl-3-(1-methyl-1H-imidazol-4-yl)-4-((4-(trifluoromethyl)phenyl)amino)benzenesulfonamide including the price, delivery time and more detailed …
Formel:
C18H17F3N4O2S
Reinheit:
Min. 95%
Molekulargewicht:
410.4 g/mol
Ref: 3D-QRD60813
| 10mg | Nachfragen | ||
| 25mg | Nachfragen | ||
| 50mg | Nachfragen |
Voraussichtliche Lieferung in Vereinigte Staaten, am Dienstag 21. Januar 2025
VT103
CAS:2290608-13-6
VT103, an oral TEAD1 palmitoylation inhibitor, shows promise against various cancers by disrupting YAP/TAZ-TEAD interactions.
Formel:
C18H17F3N4O2S
Reinheit:
98.73%
Farbe und Form:
Liquid
Molekulargewicht:
410.41
Ref: TM-T62077
| 1mg | 121,00 € | ||
| 5mg | 291,00 € | ||
| 10mg | 461,00 € | ||
| 25mg | 828,00 € | ||
| 50mg | 1.345,00 € | ||
| 100mg | 1.841,00 € | ||
| 1mL*10mM (DMSO) | 320,00 € |
Voraussichtliche Lieferung in Vereinigte Staaten, am Dienstag 28. Januar 2025
